Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

E-Z-EM ships CO(2)ject:

This article was originally published in Clinica

Executive Summary

E-Z-EM has begun overseas shipment of its CO(2)ject angiographic injector. The system uses CO(2) as a replacement for the more expensive iodinated contrast media, says the company. E-Z-EM president Daniel Martin claims the company has eliminated the "allergic reactions that can occur with iodinated contrast, with no risk of renal and hepatic toxicity". The use of CO(2) as a contrast medium improves imaging of difficult areas, is less expensive than other agents and less traumatic for the patient, says Mr Martin. The system is undergoing Phases II/III trials in the US and Canada and is already approved in Spain and Australia.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel